(2025)
Optimized cell-based platform for platelet-free detection of heparin-induced thrombocytopenia antibodies.
Adv Biol (Weinh) 9(10),
e00079.
Prof. Dr. Peter F. Zipfel
Infection Biology · Head International Leibniz Research School · Speaker +49 3641 532-1301 peter.zipfel@leibniz-hki.deCurriculum vitae
Main Research Areas
- Immune escape of human pathogenic micro-organisms
- Infection-associated function of the complement system
- Genetic susceptibility for infections
Professional Career
| Since 2000 | Professor for infection biology, Friedrich-Schiller-University Jena (FSU Jena) |
| Since 2000 | Head of the department infection biology, Leibniz-Institute for Natural Product Research and Infection Biology – Hans-Knöll-Institute Jena |
| 1999 | Nontenured professor, University Hamburg |
| 1993 | Habilitation in immunology and molecular biology, University Hamburg |
| 1989-2000 | Group head at the Bernhard-Nocht-Institute for tropical medicine Hamburg |
| 1989 | Visiting associate, Laboratory of Immunoregulation, National Institutes of Health, Bethesda, Maryland, USA |
| 1985-1988 | Postdoc, Laboratory of Immunoregulation, National Institutes of Health, Bethesda, Maryland, USA, funded by the German Academic Exchange Service (DAAD) |
| 1984 | PhD as Dr. rer. nat., University Bremen |
| 1980-1985 | Research assistant, University Bremen |
| 1980 | Diploma in biology, University Bremen |
Awards · Appointments · Scientific Activities
| Since 2009 | Member at the editorial board of molecular immunology, frontiers in innate immunity |
| 2009 | Excellence award from the Deutsche Gesellschaft für Hygiene und Mikrobiologie |
| Since 2008 | Representative of the graduate school International Leibniz Research School for Microbial and Biomolecular Interactions (ILRS) |
| 2008 | EFIS lecture award of the European Federation of Immunological Societies |
| Since 2007 | Principal investigator of the excellence graduate school Jena School for Microbial Communication (JSMC) |
| 2007 | Heinz Spitzbart award of the European Society for Infectious Diseases in Obstetrics and Gynaecology (ESIDOG) |
| Since 2006 | Principal investigator of the graduate school International Leibniz Research School for Microbial and Biomolecular Interactions (ILRS) |
| 2007-2011 | President of the European Complement Network |
| 2005 – 2012 | Board member of the European Complement Network |
| 2004 | Thuringian research award |
| Since 2002 | Deputy Director of the Leibniz-Institute for Natural Product Research and Infection Biology – Hans-Knöll-Institute Jena |
| Since 2000 | Project leader for infection biology, L2 |
| 1999-2001 | Member at the editorial board of experimental and clinical immunology, thrombosis and haemostasis, section editor molecular immunology Member of the European Working Party on the Genetics of Complement mediated Kidney Diseases, Deutsche Gesellschaft für Hygiene und Mikrobiologie (DGHM), Deutsche Gesellschaft für Immunologie, Gesellschaft für Genetik, Gesellschaft für Nephrologie |
Publications
(2025)
Combined FXIII-C3 autoantibodies and autoimmune FXIII deficiency.
JCI
[In press]
(2025)
Deletion of the mouse homolog of human FHR1 (muFHR1) alleviates Atherosclerosis in ApoE-/- mice.
Int J Med Sci
[In press]
(2025)
Factor-H-related protein 1 (FHR1), a promotor of para-inflammation in age-related macular degeneration.
J Neuroinflammation 22(1),
173.
(2025)
The 4 functional segments of Factor H: Role in physiological target recognition and contribution to disease.
J Immunol 214(9),
2150-2164.
(Review)
(2025)
Why is C5a inflammatory complement inhibition not enough to improve C3 glomerulopathy?
J Am Soc Nephrol 36(3),
345-347.
(2024)
Human and animal relationships.
In: Brakhage AA, Kniemeyer O, Zipfel PF (eds.) The Mycota - Human and animal relationships. 3. 6, pp. vii-viii. Springer, Cham.
ISBN: 978-3-031-64853. (Review)
(2024)
Unique target binding by the C-terminal region of FHR1 provides a new perception of aHUS pathology.
Front Hematol 3,
(2024)
Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity.
Front Immunol 15,
1383123.
(2023)
The role of pneumococcal extracellular vesicles on the pathophysiology of the kidney disease hemolytic uremic syndrome.
mSphere 8(4),
e0014223.
